Erythropoietin in neonatal brain protection: the past, the present and the future.

KUMRAL A., Tuzun F., Oner M. G., GENÇ Ş., Duman N., ÖZKAN H.

Brain & development, cilt.33, sa.8, ss.632-43, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 8
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.braindev.2010.10.014
  • Dergi Adı: Brain & development
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.632-43
  • Anahtar Kelimeler: Erythropoietin, Newborn, Neuroprotection, DOSE RECOMBINANT ERYTHROPOIETIN, BIRTH-WEIGHT INFANTS, WHITE-MATTER INJURY, NF-KAPPA-B, HYPOXIA-ISCHEMIA, NITRIC-OXIDE, IN-VITRO, CEREBRAL-ISCHEMIA, ENDOTHELIAL-CELLS, NEUROPROTECTIVE PROPERTIES
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Over the last decade, neuroprotective effects of erythropoietin (Epo) and its underlying mechanisms in terms of signal transduction pathways have been defined and there is a growing interest in the potential therapeutic use of Epo for neuroprotection. Several mechanisms by which Epo provides neuroprotection are recognized. In this review, we focused on the neuroprotective mechanisms of Epo and provide a short overview on both experimental and clinical studies, testing Epo as a neuroprotective agent in the neonatal brain injury, and the safety concerns with the clinical use of Epo treatment in neonates. (C) 2010 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.